The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.

Novartis’ commercial team has so far reached more than 90% of targeted doctors, the CEO said. For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S ...

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints.

Mike Exton, VP and head of the U.S. and global cardiovascular, renal and metabolism franchise at Novartis, sees the ads as hitting different notes than other pharma ads — and ones that are uniquely ...

Novartis’ Leqvio has potential to lead the cholesterol-lowering space due to its administration convenience, says GlobalData ... Sales for Novartis’ Leqvio (inclisiran) for the treatment of high ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant Novartis AG ...

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower ...